Announcement: Dr. Chih-Yi Hsieh was appointed as Chief Medical Officer of Impact Therapeutics
Impact Therapeutics announced that Dr. Chih-Yi Hsieh was appointed as Senior Vice President and Chief Medical Officer, being responsible for global clinical strategy and development of its pipeline products.
Dr. Chih-Yi Hsieh, MD, owns over ten years’ experiences in oncology clinic and global clinical trials. He was the Chief Medical Officer in ASLAN Pharmaceuticals, leading and completing multiple multinational and single-country clinical trials ranging from phase 1 to global pivotal studies. Prior to that, Dr. Hsieh was Medical Advisor at Novartis Oncology responsible for clinical studies in hematology therapeutic area. Before entering pharmaceutical industry, Dr. Hsieh was an attending physician in the Taoyuan branch, Taipei Veterans General Hospital, where he established the Divisions of Hematology and Oncology from scratch and built up a strong multidisciplinary team. Dr. Chih-Yi Hsieh holds an MD degree from the National Yang-Ming University, Taiwan, and specialist qualifications in Internal Medicine, Medical Oncology, Hematology, and in Blood and Marrow Transplantation.
Dr. Jun Bao, President and CEO, welcomed and commented: “We’re very pleased to welcome Dr. Chih-Yi Hsieh on board. Impact Therapeutics is growing up rapidly, with its first program PARP inhibitor IMP4297 into two pivotal studies in China recently, and the second program Wee1 inhibitor IMP7068 to start first-in-human study in US next year. It’s a perfect timing that Dr. Hsieh brings in his critical thinking and rich experiences to lead global clinical development towards success.”
Dr. Chih-Yi Hsieh said: “It’s very exciting to join Impact Therapeutics. Working as a team with strong innovative and executive capability, we look forward to bringing more novel anti-cancer therapies and hope to patients around the world.”
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and now is expanding to other novel synthetic lethality targets to broaden pipeline coverage. Impact has raised $46 million USD up to date invested by recognized venture capital firms including Lilly Asia Ventures. Currently series D fundraising is ongoing.